JP2015502958A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502958A5
JP2015502958A5 JP2014546103A JP2014546103A JP2015502958A5 JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5 JP 2014546103 A JP2014546103 A JP 2014546103A JP 2014546103 A JP2014546103 A JP 2014546103A JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5
Authority
JP
Japan
Prior art keywords
subject
effective amount
therapeutically effective
pathway inhibitor
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014546103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/068351 external-priority patent/WO2013086260A2/en
Publication of JP2015502958A publication Critical patent/JP2015502958A/ja
Publication of JP2015502958A5 publication Critical patent/JP2015502958A5/ja
Pending legal-status Critical Current

Links

JP2014546103A 2011-12-09 2012-12-07 がんの処置のための併用療法 Pending JP2015502958A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161568844P 2011-12-09 2011-12-09
US61/568,844 2011-12-09
US201261698030P 2012-09-07 2012-09-07
US61/698,030 2012-09-07
PCT/US2012/068351 WO2013086260A2 (en) 2011-12-09 2012-12-07 Combination therapy for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2015502958A JP2015502958A (ja) 2015-01-29
JP2015502958A5 true JP2015502958A5 (OSRAM) 2016-02-04

Family

ID=48575059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546103A Pending JP2015502958A (ja) 2011-12-09 2012-12-07 がんの処置のための併用療法

Country Status (4)

Country Link
US (1) US20150132301A1 (OSRAM)
EP (1) EP2788378A4 (OSRAM)
JP (1) JP2015502958A (OSRAM)
WO (1) WO2013086260A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6081995B2 (ja) 2011-06-17 2017-02-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 癌の処置における治療抗体の標的としてのＦｒｉｚｚｌｅｄ２
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
WO2015009851A1 (en) * 2013-07-16 2015-01-22 Icahn School Of Medicine At Mount Sinai Methods of treating cancer in subjects afflicted with metabolic dysfunction
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
HK1223657A1 (zh) * 2013-12-02 2017-08-04 Oncomed Pharmaceuticals, Inc. 與wnt途徑抑制劑有關的預測性生物標記物的鑒別
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP2975047A1 (en) * 2014-07-18 2016-01-20 Université de Lausanne Wnt7a polypeptides and their use
US20180244783A1 (en) * 2015-08-31 2018-08-30 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
US20200033346A1 (en) * 2017-03-16 2020-01-30 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic and therapeutic methods for kras positive cancers
CN107441045B (zh) * 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
CN117677398A (zh) * 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
US20230383360A1 (en) * 2021-12-16 2023-11-30 D2G Oncology, Inc. Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142481A0 (en) * 2001-04-05 2002-03-10 Yissum Res Dev Co A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof
WO2009018238A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
CA2642665C (en) * 2006-02-09 2013-01-08 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition
MX2009002936A (es) * 2006-09-19 2009-04-01 Novartis Ag Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
WO2008115890A2 (en) * 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2008138639A1 (en) * 2007-05-11 2008-11-20 Bayer Schering Pharma Aktiengesellschaft Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
US8258152B2 (en) * 2007-06-12 2012-09-04 Genentech, Inc. N-substituted azaindoles and methods of use
MX2010000716A (es) * 2007-07-18 2010-03-26 Novartis Ag Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
CN101808516B (zh) * 2007-07-30 2013-08-28 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
WO2009059994A2 (en) * 2007-11-05 2009-05-14 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
ES2456966T3 (es) * 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
CN105079805A (zh) * 2008-09-26 2015-11-25 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
KR20110132371A (ko) * 2009-03-11 2011-12-07 아디아 바이오사이언스즈 인크. Ｒｄｅａ１１９／ｂａｙ ８６９７６６을 포함하는 특정 암의 치료를 위한 제약 조합물
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
MX343368B (es) * 2010-03-09 2016-11-01 The Broad Inst Inc * Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
NZ602700A (en) * 2010-04-01 2014-10-31 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US20120231965A1 (en) * 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
CN103517710B (zh) * 2011-02-07 2017-05-31 普莱希科公司 用于激酶调节的化合物

Similar Documents

Publication Publication Date Title
JP2015502958A5 (OSRAM)
IL267609B (en) Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
HUE036583T2 (hu) Notch jelzõ folyamat inhibitorai és alkalmazásuk rákok kezelésében
PT2763982T (pt) Benzimidazois substituídos para utilização como inibidores da bub1 quinase no tratamento de doenças hiperploriferativas
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
HUE040044T2 (hu) Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
PL3489261T3 (pl) Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
IL243976A0 (en) kdm1a inhibitors for disease treatment
WO2015003360A3 (en) Therapeutically active compounds and their methods of use
EP2911669C0 (en) SYNERGIC COMBINATION OF IMMUNOLOGICAL INHIBITORS FOR THE TREATMENT OF CANCER
EP3065549A4 (en) Methods for inhibiting tie2 kinase useful in the treatment of cancer
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
PT3004108T (pt) Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
SG11201405686PA (en) Treatment of cancer with tor kinase inhibitors
PL2945642T3 (pl) Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom
ZA201607740B (en) Treatment of the complications of chronic liver disease with caspase inhibitors
PL3456333T3 (pl) Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
IL234641A0 (en) Cancer treatment with rapamycin target site kinase inhibitors
HK1223924A1 (zh) 治疗活性化合物及其使用方法
EP3050884A4 (en) Novel chemical compounds (variants) and the use thereof to treat oncological diseases
JP2013231052A5 (OSRAM)